Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Feedback Launches Bleepa Pilot Study; Continues TexRAD Review

18th Nov 2019 10:51

(Alliance News) - Feedback PLC on Monday said it will conduct a pilot study with Pennine Acute Hospitals NHS Trust using its new encrypted medical communication platform Bleepa.

The stock was trading 2.4% higher in London in morning trade at 1.05 pence a share.

Feedback's Bleepa enables clinicians to access medical grade images through smartphones, tablets and desktops.

The medical imaging technology company said the study will assess how Bleepa supports the workflow of cross team referrals. It is expected to go live during December and last for three months.

The quality of data, user experience and impact on patient care are the focus of the study, feedback said, with pre and post benchmarks executed and scheduled.

"We believe that Bleepa will accelerate the process of requesting a specialist opinion from colleagues, ultimately resulting in better care for patients, faster," said Chief Executive Tom Oakley.

"Transforming clinical services by providing digital enablement is always high on our agenda and we are excited to be involved," added Pennine Acute Hospitals NHS Trust EPR Transformation Manager Libby Woodcock.

Ahead of its annual general meeting, Feedback said the strategic review for its TexRAD medical image analysis technology has shown that further clinical data is required to support a US Food & Drug Administration submission.

The additional data that is required for the TexRAD submission is being provided by independent studies at academic institutions and therefore the timing of data supplied is outside the company's control, it explained.

"We have made some product modifications to TexRAD Research in response to customer feedback and are evaluating the impact of these on revenue. In the near term, we will continue to sell TexRAD within the research setting through third party distributors which provides a more cost-effective avenue for maintaining our sales efforts. As a result, we have reduced the resources associated with TexRAD," said Oakley.

By Evelina Grecenko; [email protected]

Copyright 2019 Alliance News Limited. All Rights Reserved.


Related Shares:

Feedback
FTSE 100 Latest
Value8,275.66
Change0.00